R. Dziadziuszko

发表

Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.

A. Chella, L. Crinò, G. Ceresoli, 2019, The Lancet. Oncology.

MA12.06 STELLAR – Final Results of a Phase 2 Trial of TTFields with Chemotherapy for First-Line Treatment of Malignant Pleural Mesothelioma

A. Chella, L. Crinò, G. Ceresoli, 2018, Journal of Thoracic Oncology.

Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).

G. Giaccone, E. Smit, P. Postmus, 2003, European journal of cancer.

Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I–III Non–Small-Cell Lung Cancer

K. Owzar, Wei Zhang, F. Hirsch, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Serum lipid profile discriminates patients with early lung cancer from healthy controls.

R. Dziadziuszko, J. Jassem, W. Rzyman, 2017, Lung cancer.

Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes.

Marcin Skrzypski, Amelia Szymanowska-Narloch, Ewa Jassem, 2013, Clinical lung cancer.

Lung cancer — the clinical benefits of treatment with ALK inhibitors in light of economic constraints in Poland

R. Dziadziuszko, Rafał Zyśk, 2015 .

Galectin-9 in non-small cell lung cancer.

F. Hirsch, R. Dziadziuszko, Xiaoshen Zhang, 2019, Lung Cancer.

Lung cancer chemoprevention - focus on surrogate markers

F. Hirsch, R. Dziadziuszko, J. Jassem, 2005 .

Cardiovascular complications after radiotherapy.

R. Dziadziuszko, G. Raczak, E. Lewicka, 2013, Cardiology journal.

K. Syrigos, D. Gandara, R. Dziadziuszko, 2017 .

Abstract B25: Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686.

P. Angenendt, H. Wakelee, L. Sequist, 2013 .

ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC).

F. Hirsch, P. Bunn, R. Dziadziuszko, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Blood First Assay Screening Trial (BFAST) in Treatment-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort.

T. Mok, S. Peters, F. de Marinis, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer

F. Hirsch, R. Dziadziuszko, J. Jassem, 2012, Journal of Thoracic Oncology.

Nazartinib in EGFR Thr790Met-mutant non-small-cell lung cancer.

R. Dziadziuszko, J. Jassem, 2020, The Lancet. Respiratory medicine.

O10.3Rociletinib: an oral, irreversible, highly selective small molecule inhibitor of mutant EGFR including T790M

J. Neal, H. Wakelee, L. Sequist, 2015 .

High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts)

F. Hirsch, P. Bunn, W. Franklin, 2007 .

Pulsed-dose-rate peri-operative brachytherapy as an interstitial boost in organ-sparing treatment of breast cancer

R. Dziadziuszko, J. Jassem, J. Jaśkiewicz, 2016, Journal of contemporary brachytherapy.

Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib

A. Drilon, T. Wilson, R. Doebele, 2022, Molecular oncology.

LAG‐3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD‐1/PD‐L1 and Tumor‐Infiltrating Lymphocytes

F. Hirsch, R. Dziadziuszko, C. Rivard, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

F. Hirsch, R. Dziadziuszko, C. Rivard, 2017, Medical science monitor : international medical journal of experimental and clinical research.

Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.

R. Dziadziuszko, J. Jassem, A. Wrona, 2018, Cancer treatment reviews.

Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.

Å. Borg, R. Dziadziuszko, J. Jassem, 2006, Lung cancer.

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

T. Gorlia, A. Dingemans, E. Felip, 2022, Scientific Reports.

The Insulin-Like Growth Factor Pathway in Lung Cancer

F. Hirsch, R. Dziadziuszko, D. Camidge, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practice.

D. de Ruysscher, R. Dziadziuszko, P. van Houtte, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A lack of correlation between mast cells, angiogenesis, and outcome in non-small cell lung cancer

R. Dziadziuszko, L. Chyczewskî, A. Zalewska, 2012, Experimental lung research.

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.

A. Warth, A. Marchetti, L. Bubendorf, 2019, Lung cancer.

P2-073: High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated patients with non-small cell lung cancer (NSCLC)

F. Hirsch, P. Bunn, R. Dziadziuszko, 2007 .

EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?

R. Dziadziuszko, J. Jassem, 2013, The Lancet. Oncology.

P53 and K‐ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma

R. Dziadziuszko, J. Jassem, M. Żylicz, 2004, Cancer.

MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC).

R. Dziadziuszko, J. Jassem, M. Żylicz, 2004, Lung cancer.

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer

F. Hirsch, R. Dziadziuszko, J. Jassem, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.

S. Novello, F. de Marinis, R. Dziadziuszko, 2020, Lung cancer.

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors

R. Dziadziuszko, M. Skrzypski, A. Szymanowska-Narloch, 2017, Contemporary oncology.

First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay.

F. Hirsch, P. Bunn, D. Gandara, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer

Kenneth L. Jones, P. Bunn, M. Varella‐Garcia, 2018, Clinical Cancer Research.

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

F. Hirsch, C. Watkins, P. Bunn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

M03-04: Selecting lung cancer patients to targeted therapies based on protein expression by immunohistochemistry

F. Hirsch, R. Dziadziuszko, F. Hirsch, 2007 .

MHC class II expression in lung cancer.

F. Hirsch, R. Dziadziuszko, C. Rivard, 2017, Lung cancer.

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

F. Cappuzzo, A. Gazdar, F. Hirsch, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Epidermal growth factor receptor (EGFR) immunohistochemistry: Comparison of antibodies (Abs) and cut points to predict benefit from gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer (NSCLC)

F. Hirsch, C. Watkins, P. Bunn, 2007 .

Fluorescence in situ hybridization (FISH) subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in NSCLC

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2007 .

Identification of serum proteome components associated with progression of non-small cell lung cancer.

R. Dziadziuszko, K. Polański, W. Rzyman, 2014, Acta biochimica Polonica.

Loss of heterozygosity at chromosomes 3p and 17p in primary non-small cell lung cancer.

R. Dziadziuszko, J. Jassem, E. Jassem, 2004, Anticancer research.

Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.

C. Dooms, N. Girard, H. Gietema, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Miliary brain metastases in a patient with ROS1-rearranged lung adenocarcinoma: a case report.

R. Dziadziuszko, J. Jassem, E. Szurowska, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic significance of dose intensity and haematological toxicity in breast cancer patients administered with adjuvant CMF chemotherapy

R. Dziadziuszko, J. Jassem, B. Radecka, 2014 .

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Y. Drew, R. Dziadziuszko, R. Ramlau, 2021, Cancer Chemotherapy and Pharmacology.

Palliative irradiation of bone metastases: patterns of care with focus on single fraction treatment

R. Dziadziuszko, J. Jassem, M. Wełnicka-Jaśkiewicz, 2004 .

Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.

G. Giaccone, P. Postmus, R. Dziadziuszko, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary

P. Krawczyk, W. Olszewski, R. Dziadziuszko, 2022, Cancers.

Radiation dose to the left anterior descending coronary artery during interstitial pulsed-dose-rate brachytherapy used as a boost in breast cancer patients undergoing organ-sparing treatment

R. Dziadziuszko, K. Serkies, M. Sinacki, 2017, Journal of contemporary brachytherapy.

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

S. Novello, R. Dziadziuszko, J. Wolf, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents

R. Dziadziuszko, J. Jassem, A. Wrona, 2021, Translational lung cancer research.

T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer.

F. Hirsch, R. Dziadziuszko, Hui Yu, 2019, Translational lung cancer research.

Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?

R. Dziadziuszko, G. Curigliano, I. Gutiérrez-Ibarluzea, 2022, Healthcare.

Prognostic relevance of mdm2 protein expression in non-small cell lung cancer

R. Dziadziuszko, J. Jassem, E. Jassem, 2006 .

STK11 and KEAP1 Mutations in Lung Adenocarcinoma: Solving the Puzzle Continues.

R. Dziadziuszko, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer?

F. Hirsch, R. Dziadziuszko, Xiaoshen Zhang, 2019, Translational lung cancer research.

TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study.

A. Shaw, S. Ou, T. Mok, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

A. Drilon, R. Doebele, R. Dziadziuszko, 2018, Journal of Thoracic Oncology.

Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

F. Cappuzzo, D. de Ruysscher, S. Novello, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.

R. Dziadziuszko, A. Filippi, I. Diaz Perez, 2021, Future oncology.

Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts.

F. Cappuzzo, D. de Ruysscher, D. Ruysscher, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Chemotherapy with mitomycin c, ifosfamide, and cisplatin for recurrent or persistent cervical cancer

R. Dziadziuszko, J. Jassem, K. Serkies, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

A. Drilon, M. Ahn, R. Doebele, 2022, JTO clinical and research reports.

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

A. Drilon, T. Wilson, M. Ahn, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC)

R. Dziadziuszko, J. Jassem, A. Lewandowska, 2005, British Journal of Cancer.

Two autologous transplants in the treatment of patients with Hodgkin's lymphoma: Analysis of prognostic factors and comparison with a single procedure

R. Dziadziuszko, J. Czyż, A. Skotnicki, 2007, Leukemia & lymphoma.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment: Results of a Randomized Phase II Study

R. Dziadziuszko, M. Krzakowski, D. Kowalski, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

G. Demetri, R. Doebele, R. Dziadziuszko, 2019, Annals of Oncology.

Prognostic value of S-100 immunostaining in tumour cells of non-small cell lung cancer

R. Dziadziuszko, J. Jassem, E. Jassem, 2006, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

D. Gandara, Melissa L. Johnson, S. Novello, 2022, Nature Medicine.

Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.

R. Dziadziuszko, G. Weiss, J. Infante, 2015 .

Blue-dye intraoperative sentinel lymph node mapping in early non-small cell lung cancer.

R. Dziadziuszko, J. Jassem, J. Skokowski, 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

S. Peters, E. Felip, F. de Marinis, 2020, ESMO Open.

The Influence of Radiotherapy on the Function of the Left and Right Ventricles in Relation to the Radiation Dose Administered to the Left Anterior Descending Coronary Artery—From a Cardiologist’s Point of View

R. Dziadziuszko, E. Lewicka, Z. Lewicka-Potocka, 2022, Cancers.

High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group

K. Sułek, R. Dziadziuszko, A. Nagler, 2002, Bone Marrow Transplantation.

Early results of a trimodality treatment for superior sulcus tumors

R. Dziadziuszko, W. Rzyman, W. Sawicka, 2014, Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery.

Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement

P. Iyengar, A. Bezjak, J. Bradley, 2020, Radiotherapy and Oncology.

Beneath the blood brain barrier: the challenge of diagnosis and management of central nervous system involvement in ALK-positive lung cancer.

R. Dziadziuszko, J. Jassem, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts

N. Girard, H. Gietema, G. Scagliotti, 2018, Journal of Thoracic Oncology.

Decortication in chronic pleural empyema - effect on lung function.

R. Dziadziuszko, J. Skokowski, W. Rzyman, 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer

Rafal Dziadziuszko, Johannes Noe, Rafael Rosell, 2017, The New England journal of medicine.

Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain

R. Dziadziuszko, J. Jassem, W. Kozlowski, 2012, Breast Cancer Research.

Conservative treatment for carcinoma of the anus--a report of 35 patients.

R. Dziadziuszko, J. Jassem, K. Serkies, 2003, Neoplasma.

Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse

F. Hirsch, R. Dziadziuszko, Jie Chen, 2021, Translational lung cancer research.

ALK alterations in salivary gland carcinomas

R. Dziadziuszko, J. Jassem, R. Menon, 2020, Virchows Archiv.

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).

U. Dafni, E. Smit, R. Stahel, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations].

P. Krawczyk, W. Olszewski, R. Dziadziuszko, 2014, Pneumonologia i alergologia polska.

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

J. Minna, L. Girard, A. Gazdar, 2006, Cancer research.

Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours

C. Montesano, R. Dziadziuszko, W. Rzyman, 2020, Cancers.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

J. Neal, H. Wakelee, L. Sequist, 2015, The New England journal of medicine.

MicroRNA in lung cancer diagnostics and treatment.

R. Dziadziuszko, J. Jassem, M. Skrzypski, 2011, Mutation research.

PD‐L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer

F. Hirsch, R. Dziadziuszko, D. Gao, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic relevance of mdm 2 protein expression in non-small cell lung cancer

R. Dziadziuszko, J. Jassem, E. Jassem, 2007 .

Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.

S. Peters, R. Dziadziuszko, S. Zimmermann, 2014, Cancer treatment reviews.

Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective.

F. Hirsch, R. Dziadziuszko, F. Hirsch, 2008, Clinical lung cancer.

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.

N. Pavlakis, A. Shaw, T. Mok, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.

P. Jänne, I. Wistuba, L. Sequist, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)

R. Dziadziuszko, J. Jassem, Małgorzata Łazar-Poniatowska, 2021, Translational lung cancer research.

International Association for the Study of Lung Cancer (IASLC)

G. Scagliotti, I. Wistuba, C. Swanton, 2019, Annals of Oncology.

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Roman K. Thomas, F. Cappuzzo, E. Smit, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased Insulin-Like Growth Factor 1 Receptor Protein Expression and Gene Copy Number in Small Cell Lung Cancer

F. Hirsch, R. Dziadziuszko, F. Gaire, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

H. Wakelee, L. Sequist, S. Ou, 2014 .

Role of Postoperative Radiotherapy in the Management for Resected NSCLC - Decision Criteria in Clinical Routine Pre- and Post-LungART.

D. de Ruysscher, R. Dziadziuszko, P. van Houtte, 2021, Clinical Lung Cancer.

[Updated recommendations on systemic treatment of non-small cell lung cancer and malignant pleural mesothelioma].

W. Olszewski, R. Dziadziuszko, R. Ramlau, 2010, Pneumonologia i alergologia polska.

Clinical implications of molecular abnormalities in lung cancer.

R. Dziadziuszko, J. Jassem, E. Jassem, 1998, Cancer treatment reviews.

Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy.

F. Hirsch, P. Bunn, W. Franklin, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer

F. Cappuzzo, F. Hirsch, P. Bunn, 2006, Clinical Cancer Research.

Prognostic Significance of Wnt1, Wnt2, E-Cadherin, and β-catenin Expression in Operable Non-small Cell Lung Cancer

R. Dziadziuszko, J. Jassem, A. Sejda, 2021, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study

A. Nicholson, I. Petersen, L. Chirieac, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.

R. Dziadziuszko, J. Jassem, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

R. Gray, R. Caprioli, P. Massion, 2007, Journal of the National Cancer Institute.

Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial

A. Shaw, S. Ou, T. Mok, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Loss of STING expression is prognostic in non–small cell lung cancer

F. Hirsch, R. Dziadziuszko, Z. Lohinai, 2022, Journal of surgical oncology.

Activation of RAS family members confers resistance to ROS1 targeting drugs

M. Varella‐Garcia, R. Doebele, R. Dziadziuszko, 2014, Oncotarget.

Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer

R. Dziadziuszko, D. Fennell, N. Leighl, 2011, British Journal of Cancer.

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

F. Hirsch, P. Bunn, R. Dziadziuszko, 2014, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFRTKI Sensitivity across All LungCancer Histologies

F. Hirsch, P. Bunn, R. Dziadziuszko, 2014 .

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

R. Dziadziuszko, G. Weiss, W. Su, 2019, British Journal of Cancer.

[Systemic treatment of non-small cell lung cancer--recommendations based on the results of reliable clinical trials].

W. Olszewski, R. Dziadziuszko, R. Ramlau, 2007, Pneumonologia i alergologia polska.

Recommendations on the systemic treatment of non-small cell lung cancer:a Round Table Conference

W. Olszewski, R. Dziadziuszko, R. Ramlau, 2005 .

Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland.

P. Krawczyk, J. Milanowski, W. Olszewski, 2017, Oncology letters.

The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.

S. Novello, R. Dziadziuszko, T. Berghmans, 2017, Clinical lung cancer.

Epidermal Growth Factor Receptor Mutation-Positive Non–Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study

W. Olszewski, H. Popper, R. Dziadziuszko, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.

F. Hirsch, P. Bunn, W. Franklin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number

R. Dziadziuszko, J. Jassem, A. Szczesna, 2016, Oncotarget.

The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study

P. Krawczyk, J. Milanowski, R. Dziadziuszko, 2014, Journal of Cancer Research and Clinical Oncology.

Chemotherapy of advanced non-small-cell lung cancer: current landscape

R. Dziadziuszko, M. O'Brien, A. Pallis, 2013 .

Lung function in patients operated for chronic pleural empyema.

R. Dziadziuszko, J. Skokowski, W. Rzyman, 2005, The Thoracic and cardiovascular surgeon.

Serum mass profile signature as a biomarker of early lung cancer.

R. Dziadziuszko, J. Jassem, W. Rzyman, 2016, Lung cancer.

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy

D. Ettinger, F. Cappuzzo, E. Smit, 2016, ESMO Open.

The influence of blood transfusion on survival in operated non-small cell lung cancer patients.

R. Dziadziuszko, J. Jassem, J. Skokowski, 2003, The Journal of thoracic and cardiovascular surgery.

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

A. Drilon, T. Wilson, C. Chung, 2019, The Lancet. Oncology.

Relative dose intensity (RDI) relevance in adjuvant CMF chemotherapy of breast cancer

R. Dziadziuszko, J. Jassem, E. Szutowicz, 2006 .

Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the Ph III study OAK

D. Gandara, R. Dziadziuszko, J. Mazières, 2018, Pneumologie.

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

P. Jänne, P. Ascierto, P. V. Van Schil, 2020, Annals of Oncology.

Epidermal Growth Factor Receptor Targeted Therapy—Markers of Sensitivity and Response

F. Hirsch, R. Dziadziuszko, B. Szostakiewicz, 2016 .

Risk factors for brain relapse in HER2-positive metastatic breast cancer patients

R. Dziadziuszko, C. Szczylik, E. Starosławska, 2009, Breast Cancer Research and Treatment.

Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement

P. Iyengar, A. Bezjak, J. Bradley, 2020, International Journal of Radiation Oncology*Biology*Physics.

Contralateral esophageal sparing technique in definitive radiotherapy for non-small cell lung cancer: dosimetric parameters and normal tissue complication probability modeling

R. Dziadziuszko, J. Jassem, J. Kamińska, 2022, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

Postoperative radiotherapy combined with 5-fluorouracil in patients with rectal cancer

R. Dziadziuszko, J. Jassem, M. Wełnicka-Jaśkiewicz, 2000 .

IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy.

D. Gandara, S. Peters, R. Dziadziuszko, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Of mice and men: olfactory neuroblastoma among animals and humans.

R. Dziadziuszko, P. Czapiewski, W. Biernat, 2016, Veterinary and comparative oncology.

Intraoperative, radio-guided sentinel lymph node mapping in 110 nonsmall cell lung cancer patients.

Rafal Dziadziuszko, Witold Rzyman, Jacek Jassem, 2006, The Annals of thoracic surgery.

NSCLC molecular testing in Central and Eastern European countries

W. Olszewski, R. Dziadziuszko, I. Kovalszky, 2018, BMC Cancer.

Evaluation of NGS and RT‐PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project

C. Dooms, K. Nackaerts, A. Warth, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Primary malignant fibrous histiocytoma of the lung.

R. Dziadziuszko, A. Karmoliński, W. Rzyman, 2007, The Thoracic and cardiovascular surgeon.

The role of EGFR tyrosine kinase inhibitors in the treatment of non-small cell lung cancer

R. Dziadziuszko, J. Jassem, A. Kowalczyk, 2005 .

Interleukin 12 augments natural killer-cell mediated cytotoxicity in hairy cell leukemia.

R. Dziadziuszko, J. Myśliwska, A. Myśliwski, 1993, Leukemia & lymphoma.

Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients.

K. Sułek, R. Dziadziuszko, A. Nagler, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Fluorescence In situ Hybridization Subgroup Analysis ofTRIBUTE , a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non ^ Small Cell Lung Cancer

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2008 .

Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2006, Clinical Cancer Research.

Epidermal Growth Factor Receptor Messenger RNAExpression , Gene Dosage , and Gefitinib Sensitivity in Non ^ Small Cell Lung Cancer

F. Cappuzzo, F. Hirsch, P. Bunn, 2006 .

Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.

R. Dziadziuszko, A. Italiano, S. Evers, 2021 .

Folate/homocysteine metabolism and lung cancer risk among smokers

R. Dziadziuszko, J. Jassem, W. Rzyman, 2019, PloS one.

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer

F. Hirsch, M. Varella‐Garcia, R. Dziadziuszko, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

1299O_PRPrimary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)

S. Novello, R. Dziadziuszko, J. Mazières, 2017 .

1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial

G. Giaccone, D. Galetta, E. Felip, 2020, Annals of Oncology.

Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance.

R. Dziadziuszko, J. Jassem, T. Soussi, 2001, Lung cancer.

Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study.

R. Dziadziuszko, K. Polański, J. Jassem, 2017, Acta biochimica Polonica.

OA02.07 Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses

S. Novello, R. Dziadziuszko, J. Mazières, 2019, Journal of Thoracic Oncology.

Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 - Systematic review and meta-analysis.

R. Dziadziuszko, S. Popat, M. Bienkowski, 2021, Lung cancer.

Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib

R. Dziadziuszko, D. Planchard, E. Guerini, 2022, ESMO open.

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer

R. Dziadziuszko, J. Mazières, K. Trunzer, 2022, ESMO open.

Lung Cancer in Poland.

P. Krawczyk, W. Olszewski, R. Dziadziuszko, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification.

R. Dziadziuszko, J. Jassem, E. Jassem, 2000, The Journal of thoracic and cardiovascular surgery.

Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC

A. Shaw, S. Ou, T. Mok, 2019, Annals of Oncology.

LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

U Nestle, D De Ruysscher, D. de Ruysscher, 2015, The British journal of radiology.

P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC: Topic: Miscellaneous

Keunchil Park, R. Dziadziuszko, Dong-Wan Kim, 2017 .

ATALANTE-1 randomized phase III trial, OSE-2101 versus standard treatment as second or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients

G. Giaccone, E. Felip, R. Dziadziuszko, 2019, Annals of Oncology.

Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients

R. Dziadziuszko, M. Krzakowski, A. Płużański, 2020, ESMO Open.

1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C

T. Mok, D. Gandara, S. Novello, 2021, Annals of Oncology.

Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland.

J. Milanowski, R. Dziadziuszko, R. Ramlau, 2020, Advances in respiratory medicine.

The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: Patient selection among ESTRO experts.

D. de Ruysscher, R. Dziadziuszko, P. van Houtte, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC).

V. Budach, R. Dziadziuszko, M. Krause, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Phase III randomised trial Final results of the randomized phase III CHARTWEL-trial ( ARO 97-1 ) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer ( NSCLC )

V. Budach, R. Dziadziuszko, M. Krause, 2011 .

Trimodality Treatment of Superior Sulcus Non-Small Cell Lung Cancer: An Institutional Series of 47 Consecutive Patients

R. Dziadziuszko, R. Dziedzic, W. Rzyman, 2023, Current oncology.

ALINA: a phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB-IIIA anaplastic lymphoma kinase-positive (ALK +) non-small cell cancer (NSCLC)

A. Shaw, J. Ahn, R. Dziadziuszko, 2019, Pneumologie.

1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline

A. Drilon, M. Ahn, R. Doebele, 2020 .

Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of vascular endothelial growth factor (VEGF) and its receptor FLK-1 in non-small cell lung cancer (NSCLC)--a preliminary report.

R. Dziadziuszko, J. Jassem, E. Jassem, 2001, Folia Histochemica et Cytobiologica.

Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative review

R. Dziadziuszko, J. Jassem, M. Skrzypski, 2023, Translational lung cancer research.

CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab

R. Dziadziuszko, M. Lewandowska, A. Kowalczyk, 2015, Molecular Diagnosis & Therapy.

OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.

F. Hirsch, R. Dziadziuszko, Xiaoshen Zhang, 2019, Translational lung cancer research.

Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (CP) in chemotherapy-naive advanced NSCLC: Correlation of biomarker status and clinical benefit.

F. Hirsch, P. Bunn, W. Franklin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor immunohistochemistry

F. Hirsch, C. Watkins, P. Bunn, 2008, Cancer.

Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study.

A. Shaw, T. Mok, S. Peters, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Ten years of experience in lung cancer screening in Gdańsk, Poland: a comparative study of the evaluation and surgical treatment of 14 200 participants of 2 lung cancer screening programmes†.

R. Dziadziuszko, R. Dziedzic, W. Rzyman, 2019, Interactive cardiovascular and thoracic surgery.

Combined analysis of P53 Arg72Pro, GSTM1 and GSTT1 gene polymorphisms as predisposing factors for non-small cell lung cancer (NSCLC) development

Å. Borg, R. Dziadziuszko, J. Jassem, 2005 .

Small-Cell Lung Cancer: Therapeutic Changes

P. Bunn, R. Dziadziuszko, P. Hirsch, 2007 .

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.

P. Postmus, Keunchil Park, R. Dziadziuszko, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1‐Positive Lung Cancer

R. Camidge, M. Varella‐Garcia, R. Doebele, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Methodological recommendations for the diagnostics of EGFR gene mutations and ALK gene rearrangement in the selection of non-small-cell lung cancer patients to molecularly targeted therapies.

P. Krawczyk, R. Dziadziuszko, M. Krzakowski, 2014, Pneumonologia i alergologia polska.

A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: The ETOP NICHE trial.

U. Dafni, E. Smit, R. Stahel, 2017 .

Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.

A. Shaw, S. Ou, T. Mok, 2020 .

1781MO IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer

A. Mansfield, T. Mok, R. Dziadziuszko, 2020 .

Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2008, Clinical Cancer Research.

RTOG 0324: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients with stage IIIA/B non-small cell lung cancer (NSCLC)--Association between EGFR gene copy number and patients' outcome

W. Curran, H. Choy, F. Hirsch, 2008 .

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

A. Drilon, G. Demetri, T. Wilson, 2022, Clinical Cancer Research.

Abstract 3190: Genomic profiling of salivary gland tumors identifies novel and targetable alterations

R. Dziadziuszko, J. Jassem, R. Menon, 2016 .

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.

A. Drilon, G. Demetri, T. Wilson, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2

A. Drilon, T. Wilson, A. Shaw, 2019, Annals of Oncology.

Continuous 7-days-a-week external beam irradiation in locally advanced cervical cancer: final results of the Phase I/II study.

R. Dziadziuszko, J. Jassem, K. Serkies, 2012, International journal of radiation oncology, biology, physics.

Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

F. Hirsch, K. Kelly, P. Bunn, 2006, Clinical Cancer Research.

Whole Brain Radiotherapy for Patients with Non-Small Cell Lung Cancer with EGFR Mutations-Why and When?

R. Dziadziuszko, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?

E. Giovannetti, G. Peters, R. Dziadziuszko, 2023, International journal of molecular sciences.

Radiotherapy and targeted drugs

R. Dziadziuszko, 2012 .

Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer

Wei Zhang, Soma Das, F. Hirsch, 2011, Clinical Cancer Research.

OA 05.07 Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK+ Metastatic NSCLC

P. Postmus, Keunchil Park, R. Dziadziuszko, 2017 .

1346PCNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC

S. Novello, R. Dziadziuszko, J. Mazières, 2017 .

1298O_PRAlectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study

A. Shaw, S. Ou, T. Mok, 2017 .

The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers.

F. Hirsch, R. Dziadziuszko, D. Camidge, 2009, Clinical lung cancer.

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.

R. Dziadziuszko, J. Mazières, P. Garrido, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantitative immunohistochemistry in lung cancer: clinical perspective.

R. Dziadziuszko, E. Szutowicz, 2010, Folia histochemica et cytobiologica.

Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations

R. Dziadziuszko, M. Blaszkowska, Z. Specht-Szwoch, 2022, ESMO open.

Increased plasma concentration of 4-pyridone-3-carboxamide-1-ß-D-ribonucleoside (4PYR) in lung cancer. Preliminary studies

R. Dziadziuszko, W. Rzyman, J. Polańska, 2019, Nucleosides, nucleotides & nucleic acids.

Short Communication: Management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: A survey of practice

D. de Ruysscher, R. Dziadziuszko, C. Faivre-Finn, 2018, Cancer treatment and research communications.

Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations

R. Dziadziuszko, G. Mountzios, A. Płużański, 2023, International journal of molecular sciences.

Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.

Rafal Dziadziuszko, Johannes Noe, Rafael Rosell, 2017 .

Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.

R. Dziadziuszko, J. Jassem, Jacek Jassem, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[Analysis of prognostic value of TP53 gene mutations in non-small cell lung cancer].

Å. Borg, R. Dziadziuszko, J. Jassem, 2005, Pneumonologia i alergologia polska.

Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).

L. Livi, E. Felip, P. Ward, 2023, Journal of Clinical Oncology.

Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.

C. Dooms, A. Drilon, E. Felip, 2023, Journal of Clinical Oncology.

Stereotactic body radiotherapy for central lung tumours: Author reply.

D. de Ruysscher, R. Dziadziuszko, C. Faivre-Finn, 2015, The British journal of radiology.

Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1.

E. Felip, R. Dziadziuszko, A. Delmonte, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).

K. O'Byrne, R. Dziadziuszko, L. Paz-Ares, 2023, Journal of Clinical Oncology.

Prevalence and clinical association of MET gene amplification in patients with NSCLC: results from the ETOP lungscape project

A. Warth, H. Dienemann, A. Marchetti, 2015 .

Exacerbation of diabetes related to exemestane treatment

R. Dziadziuszko, J. Jassem, E. Senkus-Konefka, 2008, Acta oncologica.

Chemotherapy with mitomycin c, ifosfamide, and cisplatin for recurrent or persistent cervical cancer

R. Dziadziuszko, J. Jassem, K. Serkies, 2005, International Journal of Gynecologic Cancer.

Brief Report: Exploratory analysis of maintenance therapy in patients with extensive-stage small cell lung cancer treated first-line with atezolizumab plus carboplatin and etoposide.

T. Mok, R. Dziadziuszko, M. Krzakowski, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort

T. Mok, R. Dziadziuszko, D. Shames, 2019, Annals of Oncology.

Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer

L. Sequist, R. Dziadziuszko, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

C. Watkins, P. Bunn, W. Franklin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

P. Bunn, R. Dziadziuszko, D. Gao, 2014, Clinical Cancer Research.

Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer

L. Sequist, R. Dziadziuszko, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bomirski Ab Melanoma as a Model of Tumor-Induced Cachexia

R. Dziadziuszko, A. Myśliwski, J. Bigda, 1992 .

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC).

H. Wakelee, L. Sequist, M. Diehn, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Insulin-Like Growth Factor Pathway in Lung Cancer

R. Dziadziuszko, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pulsed dose rate brachytherapy of lip cancer

R. Dziadziuszko, K. Serkies, J. Kamińska, 2013, Journal of contemporary brachytherapy.

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.

E. Felip, R. Dziadziuszko, T. Owonikoko, 2023, The New England journal of medicine.

Can an Integrative SNP Approach Substitute Standard Identification in Comprehensive Case/Control Analyses?

Joanna Polanska, Anna Papiez, Marcin Skrzypski, 2018, PACBB.

Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

P. Bunn, R. Dziadziuszko, M. Varella-Garcia, 2006, Clinical Cancer Research.

Predictive factors testing proposal for NSCLC patients during the COVID-19 pandemic

P. Krawczyk, R. Dziadziuszko, D. Kowalski, 2021, Expert review of anticancer therapy.